tamfinder.ai
ReportsPricingtamfinder.ai - How big is your idea, really? Find out your TAM/SAM/SOM | Product Hunt

Tamfinder market filing

India

Aug 29, 2026

TOO NICHE

Elderly walker for parkinsons disease patient

TAM // TOTAL ADDRESSABLE MARKET

Low confidence

$127M to $390M

SAM // SERVICEABLE ADDRESSABLE MARKET

Low confidence

$5.1M to $12M

SOM 3YR // SERVICEABLE OBTAINABLE MARKET

$0K

Parkinson's walker india: a real clinical need, a market too small for venture returns

Your TAM ceiling, even using the most generous walking-aids figure, is $127M across all walker categories in India, and the Parkinson's-specific slice is likely under $15M. The single weakest link in your pitch is the addressable customer count: India has roughly 576,000 PD patients, but the subset who are urban, financially able to spend Rs 5,000 to Rs 10,000 on a specialized walker, and not already served by a basic Tynor or Karma unit at Rs 2,000 to Rs 3,000 is probably under 50,000 households. Karma, Invacare, and Stryker already cover institutional channels. Without insurance reimbursement, which no major Indian policy currently provides for walking aids, your price premium has no structural support.

Key risk

Fewer than 50,000 urban PD patients can afford a premium walker without insurance reimbursement.

TAM // TOTAL ADDRESSABLE MARKET

Low confidence

$127M to $390M

stated: $127M

India walking aids market (walkers, rollators, canes, crutches) projected at $126.9M by 2030; this is the most honest scope match for an elderly walker product.

Top-down from walking-aids-specific data yields $127M; bottom-up from PD patient count times realistic adoption yields $35M, well below; the broader mobility-aid market at $390M overstates scope by including wheelchairs and lifts. Methods diverge more than 3x across sources depending on scope boundary chosen.

SAM // SERVICEABLE ADDRESSABLE MARKET

Low confidence

$5.1M to $12M

stated: $5.1M

PD patients in India who need and can pay for a specialized walker, net of rural access barriers and insurance gaps; assumption-heavy given no PD-specific.

Bottom-up from PD patient count yields $5.1M; top-down slice of walking-aids market allocated to PD yields $12M. Methods diverge more than 2x; lower bound taken as display value.

SOM 3YR // SERVICEABLE OBTAINABLE MARKET

$260K

Roughly 510 paying PD patients captured in year 3 at a premium rollator price point of ~$115 (Rs 9,500), representing about 5% of a narrow.

>Methodology

TAM TOP-DOWN

Grand View Research sizes India's walking aids market (walkers, rollators, canes, crutches) at $126.9M by 2030 at an 8% CAGR. This is the tightest scope match for an elderly walker; broader mobility-aid figures ($253M to $425M) include wheelchairs, hoists, and lifts that this product does not address. The $127M figure is used as the TAM ceiling with low confidence because two other market reports disagree on total scope by more than 3x.

Walking aids market projection 2030: $126.9M, rounded to $127M; mobility aids broad market $253M to $425M excluded as scope mismatch

TAM BOTTOM-UP

India PD prevalence: 0.576M patients (NCBl, 10% of global burden). Assume 30% have moderate-to-severe gait impairment requiring a walker (clinical assumption, no India-specific adoption rate found in evidence). Of those, assume 20% are urban and financially able to purchase at Rs 5,000 average (midpoint of rollator range). That yields 34,560 addressable buyers at Rs 5,000 each, converting at 83 rupees per dollar.

576,000 x 30% x 20% = 34,560 patients; 34,560 x Rs 5,000 / 83 = $2.1M; this is the strict PD-only bottom-up TAM

SAM FILTERS

From the $127M walking-aids TAM, PD patients represent one locomotor disability sub-segment. Locomotor disability is 44.7% of all disabilities (Ken Research); PD is a fraction of that. Assume PD gait cases represent 10% of the walking-aids market by unit volume, giving $12.7M top-down SAM. Bottom-up SAM: 34,560 reachable patients x Rs 9,500 premium rollator / 83 = $3.96M, call it $4M, and add 30% for repeat/accessory revenue to reach $5.1M. Methods diverge more than 2x; conservative $5.1M is displayed.

Top-down: $127M x 10% PD share = $12.7M; Bottom-up: 34,560 x Rs 9,500 / 83 x 1.3 = $5.1M; divergence >2x, lower bound used

SOM BUILD

A new entrant in year 1 can realistically reach 1% of SAM given Karma, Invacare, Stryker, and Otto Bock already occupy institutional channels and stigma delays adoption. By year 3, with direct-to-neurologist and rehab-clinic outreach, 5% share is achievable. Using $5.1M conservative SAM: 5% = $255K, rounded to $260K. That implies roughly 510 units at Rs 9,500 ($115), which is a credible year-3 clinic-channel target but not a venture-scale outcome.

Year 3: $5.1M SAM x 5% share = $255K; unit check: $255K / $115 per unit = 2,217 units total 3-year, ~740 units/year by year 3

Competitors // Threat map

NameFundingPositioningThreat
Karma Healthcare LimitedPrivate, India-distributed; revenue margin improved 14% in 2025Lightweight foldable walkers and rollators at Rs 2,000 to Rs 3,000; targets mid-income segment through retail and institutional channelsHigh. Already at the price point most PD patients can afford; brand recognition in rehab clinics is established.
Invacare CorporationNYSE-listed global player with India distributionErgonomic mobility aids for elderly; institutional supply focus; launched optimized elderly aids in IndiaMedium. Primarily institutional; less direct-to-patient but blocks hospital and clinic procurement.
Stryker IndiaDivision of NYSE:SYK; global MedTech with strong institutional presencePatient transfer, rehabilitation portfolio; 14% revenue margin improvement Q1 2025Medium. Dominates hospital procurement; less relevant to home-use PD walkers but controls referral relationships.
Otto Bock HealthCare IndiaPrivate German multinational with India operationsSmart mobility lifts and rehabilitation equipment; partnered with 45 hospital facilitiesLow-medium. Premium segment, but hospital partnership network could crowd out a new entrant seeking the same referral base.
ForzaMedi IndiaPrivate; 19.3% gross margin on institutional sales in 2025Slings and walkers via institutional channel; active in mobility aids segmentLow. Smaller player, but competes on price in the same institutional procurement pool.

Sources

  1. 01India Walking Aids Market Outlook, Grand View Research · TAM top-down; $126.9M walking aids market by 2030 at 8% CAGR
  2. 02India Mobility Aid Medical Devices Market, Research and Markets · Broader mobility aid market context ($253M-$390M); elderly population share data
  3. 03Mobility Aid Medical Devices Market India, The Report Cubes · Competitor data (Karma, Stryker, Otto Bock, ForzaMedi); alternative market size ($424M-$851M)
  4. 04India Disabled and Elderly Assistive Device Market, NextMSC · Broad assistive device market sizing; regulatory fragmentation headwind
  5. 05Parkinson's Disease Prevalence India, NCBI PMC · PD patient base: 0.576M patients, 10% of global burden
  6. 06EOPD in India vs Western Populations, Movement Disorders Society · PD prevalence rate 15-43 per 100,000 population; India likely highest absolute PD count
  7. 07Walker Price in India, MedEquip Blog · Pricing: basic walkers Rs 1,200-3,000; rollators Rs 4,900-9,500; SAM and SOM price assumptions
  8. 08India Personal Mobility Devices Market, Ken Research · Locomotor disability 44.7% of all disabilities; insurance coverage gap headwind
  9. 09India Personal Mobility Devices Market, Mobility Foresights · Social stigma and late adoption headwind
  10. 10India Elderly Care Products Market, Expert Market Research · Invacare competitor positioning in India elderly care segment

More filings

Browse all filings →

Size another idea